# 癌因性疲憊症之臨床治療指引

# MANAGEMENT OF CANCER-RELATED FATIGUE – A GUIDELINE FOR TAIWAN –

#### 2017年11月 第一版



Rau KM, Shun SC, Hung SH, Chou HL, Ho CL, Chao TC, Liu CY, Lien CT, Hong MY, Wu CJ, Tsai LY, Jane SW, Hsieh RK. Management of cancerrelated fatigue in Taiwan: an evidence-based consensus for screening, assessment and treatment. Jpn J Clin Oncol. 2022 Nov 9:hyac164. doi: 10.1093/jjco/hyac164.

# 癌因性疲憊評估與治療



Rau KM, Shun SC, Hung SH, Chou HL, Ho CL, Chao TC, Liu CY, Lien CT, Hong MY, Wu CJ, Tsai LY, Jane SW, Hsieh RK. Management of cancerrelated fatigue in Taiwan: an evidence-based consensus for screening, assessment and treatment. Jpn J Clin Oncol. 2022 Nov 9:hyac164. doi: 10.1093/jjco/hyac164.

癌因性疲憊症	之藥物治療		
<b>黃耆多醣注射劑</b> 有初步臨 床試驗顯示可改善中重度癌 因性疲憊症。 (Level IA, Grade A)	<b>蔘類</b> 在臨床試驗顯示可以改 善癌因性疲憊,但因中藥在 使用上會因原料製備等影響, 建議使用前應諮詢醫療團隊。 (Level IB, Grade B)		
Methylphenidate	Methylprednisolone >		
臨床研究顯示使用於疲憊程	dexamethasone等類固醇藥物		
度或病情較嚴重的病人較具	有臨床證據顯示可以改善癌		
效果;但在用藥前應審慎考			
双不, 但任用  用  應  备  俱	症病人的疲憊和生活品質,		
双禾,但在用柴前應番俱考 量劑量、用藥時間、濫用風	症病人的疲憊和生活品質, 但長期使用有安全風險,故		
量劑量、用藥時間、濫用風	但長期使用有安全風險,故		
量劑量、用藥時間、濫用風 險、及病人個人疾病等臨床	但長期使用有安全風險,故 建議只用於癌症末期、合併		

Rau KM, Shun SC, Hung SH, Chou HL, Ho CL, Chao TC, Liu CY, Lien CT, Hong MY, Wu CJ, Tsai LY, Jane SW, Hsieh RK. Management of cancerrelated fatigue in Taiwan: an evidence-based consensus for screening, assessment and treatment. Jpn J Clin Oncol. 2022 Nov 9:hyac164. doi: 10.1093/jjco/hyac164.



癌因性疲惫症之臨床治療指

31

MANAGEMENT OF CANCER-RELATED FATIGUE - A GUDEINE FOR TAMAN

#### 遍因性疲憊症 之臨床治療指引 MANAGEMENT OF CANCER-RELATED FATIGUE

A GUIDELINE FOR TAIWAN -





癌因性疲憊症之臨 床治療指引電子版 連結由此去



## 癌因性疲憊症的病人衛教資訊

### 衛教單張與日誌

以淺白的語言,介紹有關癌因性疲憊症的重要資訊,醫護 人員有需要可自行影印供病人及其家屬閱讀。然而,衛教 單張的提供並不能取代面對面的病人教育。

### 內容項目:

- 認識癌因性疲憊症
- 溝通
- 自我評估
- 非藥物和藥物治療
- 病人的責任
- 日常疲憊記錄表





### 癌因性疲憊症治療醫病共享決策輔助評估表

### **SDM**

2019年本會發展癌因性疲 憊症治療醫病共享決策輔 助評估表,透過SDM協助 臨床人員說明病情,也讓 病人能清楚了解病況及選 擇合適的臨床處置。 若有需使用CRF-SDM, 歡 迎向本會秘書處索取,以 取得本會授權,並請註明 出處。



台灣癌症安寧緩和醫學會 「癌因性疲憊症」治療醫病共享決策輔助評估表



你累了嗎? 擊退癌疲憊 癌症治療更完備

#### 勇敢的抗癌鬥士:

對抗癌症並不輕鬆,除了要面對癌症本身的不適症狀,也可能得承受各種治療帶 來的影響。據調查,台灣有92%的癌症病人有疲憊困擾,其中更有四分之一屬於 中重度疲憊患者。

但其實你的疲憊是可被改善的!趕快用疲憊量尺評估一下,自己有多疲憊?並了 解處置和各藥物治療優缺點,找出心目中理想的治療方式吧!

#### 什麼是癌因性疲憊症?

- 癌因性疲憊症是因癌症或癌症治療所引起之重大疲憊感, 其症狀與活動量不成比例,且足以影響到正常生活。
- 任何一種癌症、治療方式、治療藥物或治療階段,都可能發生癌因性疲憊症。



》 疲憊會降低身體活動能量、降低執行力、減少對事物的興 趣、增加心理壓力、導致睡眠困擾,影響生活品質等。

快用疲憊量尺評估自己的疲憊程度

 0 分表示沒有疲憊,10 分為想像中最嚴重的疲憊。
請根據自身疲憊的感覺,指出對應的疲憊分數, 或選擇最能代表您疲憊狀態的圖像及其對應分數。



## 愛你不累,擊退癌疲憊

衛教動畫影片 2019年延續「癌因性疲憊 症臨床治療指引」內容, 製作癌因性疲憊症民眾衛 教影片。2020年至2021年 製作衛教影片英文版及閩 南語版,包含完整版與精 華版,希冀以淺顯易懂方 式讓民眾認識癌因性疲憊 症,提供醫護人員多元衛 教方式使用。



序號	名稱		語言	發表年份	連結處
1	愛你不累,擊退癌疲憊!	-完 <mark>整版</mark>	國語	2019	
2	愛你不累,擊退癌疲憊!	-完整版	台語	2020	
3	愛你不累,擊退癌疲憊!	-完整版	英語	2020	<b>e</b>
4	愛你不累,擊退癌疲憊!	- <mark>精</mark> 華版	國語	2021	<u>.</u>
5	愛你不累,擊退癌疲憊!	-精華版	台語	2021	
6	愛你不累,擊退癌疲憊!	-精華版	英語	2021	

# 國際期刊刊登

2022年10月Japanese Journal of Clinical Oncology 刊登 <sup>r</sup> Management of Cancer-**Related Fatigue in Taiwan: An Evidence-Based Consensus for** Screening, Assessment, and Treatment」,國際看見學會 與專家們的倡議,更多醫護 人員重視癌因性疲憊的議題, 讓病人抗癌治療更順利。



Japanese Journal of Clinical Oncology, 2023, 53(1)46-56 https://doi.org/10.1033/jjco/hyac164 Advance Access Publication Date: 9 November 2022

OXFORD

#### Original Article

Management of cancer-related fatigue in Taiwan: an evidence-based consensus for screening, assessment and treatment

Kun-Ming Rau<sup>1,2,1</sup>, Shiow-Ching Shun<sup>3,1</sup>, Shih-Hsin Hung<sup>4</sup>, Hsiu-Ling Chou<sup>5,6,7</sup>, Ching-Liang Ho<sup>8,9</sup>, Ta-Chung Chao<sup>10,11</sup>, Chun-Yu Liu<sup>12,12,14</sup>, Ching-Ting Lien<sup>16</sup>, Ming-Ying Hong<sup>16</sup>, Ching-Jung Wu<sup>17,18,19</sup>, Li-Yun Tsai<sup>20</sup>, Sui-Whi Jane<sup>21,22</sup> and Ruey-Kuen Hsieh<sup>23,\*</sup>

<sup>1</sup>Department of Hematology Oncology, E-Da Cancer Hospital, Kaohsiung, Taiwan, <sup>2</sup>School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan, <sup>3</sup>College of Nursing, Institute of Clinical Nursing, National Yang Ming Chiao Tung University, Taipei, Taiwan, <sup>4</sup>Department of Nursing, Taipei Veterans General Hospital, Taipei, Taiwan, <sup>5</sup>Department of Nursing, Asia Eastern University of Science and Technology, New Taipei City, Taiwan, <sup>6</sup>Department of Nursing, Far Eastern Memorial Hospital, New Taipei City, Taiwan, <sup>7</sup>School of Nursing, National Yang Ming Chiao Tung University, Taipei, Taiwan, <sup>8</sup>Division of Hematology and Oncology, Tri-Service General Hospital, Tainei Taiwan <sup>9</sup>Division of Opcology, National Defense Medical Center, Tainei, Taiwan, <sup>10</sup>Department of Opcology and Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei, Taiwan, <sup>11</sup>Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, <sup>12</sup> Division of Transfusion Medicine, Department of Medicine and Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei, Taiwan, <sup>18</sup>Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, <sup>14</sup>School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, <sup>15</sup>Department of Nursing, MacKay Memorial Hospital, Taipei, Taiwan, <sup>16</sup>Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan, <sup>17</sup>Department of Radiation Oncology, Cathay General Hospital, Taipei, Taiwan, <sup>18</sup>Department of Radiation Oncology, National Defense Medical Center, Taipei, Taiwan, <sup>19</sup>Department of Biomedical Engineering, I-Shou University, Kaohsiung, Taiwan, <sup>20</sup>College of Nursing, Central Taiwan University of Science and Technology, Taichung, Taiwan <sup>21</sup> Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 22 Graduate Institute of Nursing, Chang Gung University of Science and Technology, Taoyuan, Taiwan and <sup>28</sup>Department of Hematology and Oncology, MacKay Memorial Hospital, Taipei, Taiwan

\*For reprints and all correspondence: Ruey-Kuen Hsieh, Department of Hematology and Oncology, MacKay Memorial Hospital, Taipei, Taiwan. No. 92, Sec. 2, Zhongshan N. Rd., Taipei City 10449, Taiwan. E-mail: hsieh.simonrk@gmail.com

 $^{\dagger}\mathsf{T}\mathsf{hese}$  authors contributed equally to the work

Received 26 May 2022, Editorial Decision 5 October 2022, Accepted 8 October 2022

#### Abstract

Background: Cancer-related fatigue is one of the most common and persistent issues experienced by cancer patients. Cancer-related fatigue is a distinct form of fatigue that is subjective, long-lastic and unalleviated by rest or seleo. Studies have shown that almost all cancer patients experience severe fatigue that disrupts the quality of life and physical function, but cancer-related fatigue remains underaddressed in clinical care, and only about half of all patients receive treatment. Methods: To increase the awareness of cancer-related fatigue and improve current management, the Taiwan Society of Cancer Palliative Medicine and the Taiwan Oncology Nursing Society

© The Author(s) 2022. Published by Oxford University Press.

This is an Open Access anticle distributed under the terms of the Creative Commons Attribution License (https://creative.commons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.



## "Cure sometimes, treat often, comfort always"

Hippocrates